Evaluation of Carboplatin Sustained-release Delivery System in Dogs with Cancer

Overview

Journal Vet Med Sci

Specialty Veterinary Medicine

Date 2017 Oct 26

PMID 29067189

Citations 1

Authors

Colleen Tansey Baldwin

Courtney H Zwahlen

Steven Kirschner

Reid K Nakamura

Affiliations

Soon will be listed here.

Abstract

The objective of the study was to assess the carboplatin sustained-release (CSR) as an injectable, biodegradable polymer system designed to uniformly release carboplatin over 30 days at a dose of 350 mg m. The study involved seven client-owned dogs with histologically or cytologically confirmed neoplasia that were treated with CSR intramuscularly. Platinum levels were measured at days 0, 7, 14, 21 and 28. Complete blood cell (CBC) counts, body weight, local toxicity and side effects were also evaluated at the time of platinum measurement at days 0, 7, 14, 21 and 28. CSR released carboplatin steadily over 30 days. Neutropenia was noted as Grade 3 in one dog (14%) and Grade 4 in two dogs (29%) at day 14, and Grade 4 in one dog (14%) at day 21. Thrombocytopenia was noted as Grade 2 in four dogs (57%), Grade 3 in one dog (14%) and Grade 4 in one dog (14%) at day 14; Grade 2 in two dogs (29%) and Grade 3 in one dog (14%) at days 21 and 28. Grade 1 lethargy in one dog (14%) and Grade 1 nausea in dog (14%) occurring within 7 days after administration. No obvious local injection site reactions were noted. CSR administered at 350 mg m intramuscularly resulted in a steady release over 30 days. Myelosuppression (Grade 4) was noted in 86% of patients. CSR released the drug slowly and steadily, however additional studies are needed to assess acceptable dosage requirements.

Citing Articles

Modified Carboxyl-Terminated PAMAM Dendrimers as Great Cytocompatible Nano-Based Drug Delivery System.

Vu M, Bach L, Nguyen D, Ho M, Nguyen N, Quyen Tran N Int J Mol Sci. 2019; 20(8).

PMID: 31022905 PMC: 6514678. DOI: 10.3390/ijms20082016.

References

Manunta M, Gavini E, Chessa G, Passino E, Careddu G, Giua S . Carboplatin sustained delivery system using injectable microspheres. J Vet Med A Physiol Pathol Clin Med. 2005; 52(8):416-22. DOI: 10.1111/j.1439-0442.2005.00751.x. View

Chun R, Knapp D, Widmer W, DeNicola D, Glickman N, Kuczek T . Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 1998; 11(5):279-83. DOI: 10.1111/j.1939-1676.1997.tb00465.x. View

Phillips B . Severe, prolonged bone marrow hypoplasia secondary to the use of carboplatin in an azotemic dog. J Am Vet Med Assoc. 1999; 215(9):1250-2; discussion 1252-3. View

Chatelut E, Pivot X, Otto J, Chevreau C, Thyss A, Renee N . A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer. 2000; 36(2):264-9. DOI: 10.1016/s0959-8049(99)00266-x. View

Chum H, Jampachairsri K, McKeon G, Yeomans D, Pacharinsak C, Felt S . Antinociceptive effects of sustained-release buprenorphine in a model of incisional pain in rats (Rattus norvegicus). J Am Assoc Lab Anim Sci. 2014; 53(2):193-7. PMC: 3966277. View

Dernell W, Withrow S, Straw R, Powers B, Drekke J, Lafferty M . Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer. Anticancer Res. 1998; 17(6D):4499-505. View

Theon A, VanVechten M, Madewell B . Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res. 1996; 57(2):205-10. View

Bailey D, Erb H, Williams L, Ruslander D, Hauck M . Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med. 2003; 17(2):199-205. DOI: 10.1111/j.1939-1676.2003.tb02434.x. View

Page R, McEntee M, George S, Williams P, Heidner G, Novotney C . Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med. 1993; 7(4):235-40. DOI: 10.1111/j.1939-1676.1993.tb01013.x. View

10.

Nunamaker E, Halliday L, Moody D, Fang W, Lindeblad M, Fortman J . Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis). J Am Assoc Lab Anim Sci. 2013; 52(1):48-56. PMC: 3548201. View

11.

Ogilvie G, Richardson R, Curtis C, Withrow S, REYNOLDS H, Norris A . Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc. 1989; 195(11):1584-7. View

12.

. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2017; 14(4):417-446. DOI: 10.1111/vco.283. View

13.

Bauer C, Frost P, Kirschner S . Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis). J Am Assoc Lab Anim Sci. 2014; 53(5):502-11. PMC: 4181692. View

14.

Bailey D, Rassnick K, Erb H, Dykes N, Hoopes P, Page R . Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors. Am J Vet Res. 2004; 65(11):1502-7. DOI: 10.2460/ajvr.2004.65.1502. View

15.

Gavini E, Manunta L, Giua S, Achenza G, Giunchedi P . Spray-dried poly(D,L-lactide) microspheres containing carboplatin for veterinary use: in vitro and in vivo studies. AAPS PharmSciTech. 2005; 6(1):E108-14. PMC: 2750418. DOI: 10.1208/pt060117. View

16.

Rassnick K, Ruslander D, Cotter S, Al-Sarraf R, Bruyette D, Gamblin R . Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc. 2001; 218(9):1444-8. DOI: 10.2460/javma.2001.218.1444. View

17.

Kisseberth W, Vail D, Yaissle J, Jeglum K, Couto C, Ward H . Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study. J Vet Intern Med. 2008; 22(1):83-8. DOI: 10.1111/j.1939-1676.2007.0017.x. View

18.

Frazier D, Price G . Use of body surface area to calculate chemotherapeutic drug dose in dogs: II. Limitations imposed by pharmacokinetic factors. J Vet Intern Med. 1998; 12(4):272-8. DOI: 10.1111/j.1939-1676.1998.tb02122.x. View

19.

Hahn K, McEntee M, Daniel G, Legendre A, Nolan M . Hematologic and systemic toxicoses associated with carboplatin administration in cats. Am J Vet Res. 1997; 58(6):677-9. View

20.

Price G, Frazier D . Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae. J Vet Intern Med. 1998; 12(4):267-71. DOI: 10.1111/j.1939-1676.1998.tb02121.x. View